Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children

References

• Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005;18:417–22.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics 1999;103:843–52.
   PubMed Web of Science ®Google Scholar
• Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, . Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008;27:85–8.
   PubMed Web of Science ®Google Scholar
• Cormican M, Morris D, Corbett-Feeeney G, Flynn J. Extended spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn Microbiol Infect Dis 1998;32:317–9.
   PubMed Web of Science ®Google Scholar
• Arpin C, Dubois V, Coulange L. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47:3506–14.
   PubMed Web of Science ®Google Scholar
• Lescure FX, Eveillard M, Douadi Y, Eb F. Community-acquired multiresistant bacteria: an emerging problem? J Hosp Infect 2001;49:149–51.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089–94.
   PubMed Web of Science ®Google Scholar
• Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, . Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004;54:735–43.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52–9.
   PubMed Web of Science ®Google Scholar
• Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003;47:273–95.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913–20.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, . Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987–94.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159–66.
   PubMed Web of Science ®Google Scholar
• Elliott E, Brink AJ, van Greune J, Els Z, Woodford N, Turton J, . In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42:e95–8.
   Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research. Pediatric exclusivity labeling charges. US FDA; 2005. Available at: http://www.fda.gov/scienceResearch/specialTopics/PediatricTherapeuticsResearch/UCM107519.htm (accessed 5 December 2006).
   Google Scholar
• Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65: 2151–78.
   PubMed Web of Science ®Google Scholar
• Hengstler KA, Hammann R, Fahr AM. Evaluation of BBL CHROMagar orientation medium for detection and presumptive identification of urinary tract pathogens. J Clin Microbiol 1997;35:2773–7.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for disk susceptibility tests for bacteria that grow aerobically. 7th. NCCLS Document M2-A7. Wayne, PA: NCCLS; 2000.
   Google Scholar
• Vranes J, Marijan T, Bedenic B, Mlinaric-Dzepina A, Katic S, Kalenic S. Clonal dissemination of highly virulent extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from the urine of non-hospitalised patients in Zagreb region. Int J Antimicrob Agents 2008;31:S19–24.
   Web of Science ®Google Scholar
• Daza R, Gutiérrez J, Piédrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001;18:211–5.
   PubMed Web of Science ®Google Scholar
• Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, . Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163–7.
   PubMed Web of Science ®Google Scholar
• Sorlózano A, Gutiérrez J, Romero JM, de Dios Luna J, Damas M, Piédrola G. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007;47:413–6.
   PubMed Web of Science ®Google Scholar
• Arguedas A, Cespedes J, Botet FA, Blumer J, Yogev R, Gesser R, . Protocol 036 Study Group. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection. Int J Antimicrob Agents 2009;33:163–7.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, . In vitro suscepibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965–73.
   PubMed Web of Science ®Google Scholar
• Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, . Protocol 021 Study Group. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002;60:16–22.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076–83.
   PubMed Web of Science ®Google Scholar
• Vetter N, Cambronero-Hernandez E, Rohlf J, Simons S, Carides A, Oliveria T, . Protocol 020 Study Group. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002;24:1770–85.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, . Protocol 017 Study Group. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235–45.
   PubMed Web of Science ®Google Scholar